Perrigo OTC Switch Kit Features Rx Generics As Handy Tool
This article was originally published in The Tan Sheet
Perrigo looks at its Rx topicals and ophthalmic and asthma products "as potential opportunities not just for the generic opportunity, which is good, but for those other opportunities coming into the OTC spot," says CEO Joseph Papa.
You may also be interested in...
The OTC drug private label giant's share price increased as much as 5% in heavy trading May 31 after the release a day earlier of its complete 2017 first-quarter earnings statement and its announcement of $1.4bn in tender offers for credit notes due starting in 2021.
Merck & Co.’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.